Early trial of AMPK activator ATX-304 reports metabolic changes
An early phase 1b trial in people with obesity or prediabetes reported improvements in liver fat, visceral fat and resting metabolic rate after 8 weeks of taking the compound ATX-304.
Source: Early trial of AMPK activator ATX-304 reports metabolic changes (x.com). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
The report describes a phase 1b trial in people with obesity or prediabetes, testing ATX-304, a compound that activates AMPK, an enzyme linked to the control of energy metabolism. According to the publication, after 8 weeks participants showed improvements in liver fat, visceral fat (the fat stored around the abdominal organs) and resting metabolic rate, meaning the energy the body burns at rest.
Phase 1b trials mainly assess safety and how a compound behaves in the human body, not whether it provides long-term health benefits. AMPK is studied as a target linked to ageing, but that connection is still under investigation. Because this is an early-stage trial, the finding is preliminary and needs confirmation in larger and longer studies before any conclusions can be drawn.
What it means
The finding suggests ATX-304 changes metabolic markers in people with obesity or prediabetes over 8 weeks. It is not yet known whether these changes translate into better health, whether the effect lasts over time, or what risks exist.
How to read it with care
This early result does not replace a medical consultation. Anyone considering a change in diet, supplements or treatment should talk to a doctor or another qualified health professional before making any decision.